As of Feb 23
| -0.10 / -0.19%|
The 18 analysts offering 12-month price forecasts for Novozymes A/S have a median target of 52.58, with a high estimate of 66.12 and a low estimate of 39.67. The median estimate represents a -0.12% decrease from the last price of 52.65.
The current consensus among 19 polled investment analysts is to Hold stock in Novozymes A/S. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.